Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

Roche HoldingsRHHBY announced that the FDA has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV). Per the company, Rituxan is the first ...

Roche has presented new data which shows Gazyva is superior to its established Rixtuxan/Mabthera in treating follicular lymphoma (FL). Rituxan/MabThera is one of Roche's biggest sellers, earning ...

Roche Holding AG RHHBY announced that the FDA approved the label expansion of Rituxan (rituximab). The agency approved the drug, in combination with glucocorticoids, for the treatment of two rare ...

Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

Obinutuzumab for induction and maintenance provides significantly higher PFS than rituximab, the current standard of care for follicular lymphoma (FL). But an editorial cautions it's too soon to tell.

PURPOSEThe PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly ... writing assistance was ...

Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx) combo to treat adults with relapsed or refractory (R/R) diffuse large ...

Rituxan/MabThera is one of Roche's biggest sellers, earning around $7 billion a year across a variety of indications, including FL and chronic lymphocytic leukemia (CLL).